[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@spontonic "Never even gave TIGIT a glance. Didn't buy into any of them post-brief CD47 flirtation. I'm not a groupie. Anti-#CCR8 is designed to work without inducing autoimmunity and preclinical and clinical results to date are encouraging. For me any good CCR8 news is $CHRS good news"
X Link @spontonic 2025-08-04T20:08Z XXX followers, 1113 engagements

"3/ For example $PFE knows how much it needs a good CCR8. Dias et al. have been quick and bright $CHRS is in the mix. So. co-develop XXX exclusive. send that tori salesforce out to sell that An aside. STORM has venture ties with PFE"
X Link @spontonic 2025-08-08T01:19Z XXX followers, XXX engagements

"$CHRS $PFE $MRK $CMPX More on companies that need CHS-114. "It hardly needs stating that biopharma has staked huge sums on PD-(L)1 x VEGF bispecifics". All of the molecules mentioned will need life extension plans"
X Link @spontonic 2025-08-13T16:19Z XXX followers, XXX engagements

"INOVIO INOVIO INOVIO SALES FORCE SALES FORCE SALES FORCE Clown virtually had tori standing on INOVIO's shoulders. It's still a focal point in slides Now he has plans to stand tori on 114's shoulders in the U.S. all while spending $XX to sell $X of it. $CHRS"
X Link @spontonic 2025-08-14T21:13Z XXX followers, XXX engagements

"Merck's footprints. clinical trial supply agreements (that won't look remotely practical to most potential partners) And the BOD does nothing. $CHRS $MRK"
X Link @spontonic 2025-08-14T21:21Z XXX followers, XXX engagements

"$CHRS "We can't seem to sell tori. I don't understand it but we need to rebrand the sales team. From this day on it's a sales FORCE Thank you for your attention to this matter.""
X Link @spontonic 2025-08-20T18:14Z XXX followers, XXX engagements

""The anti-PD-1 moiety of JS207 adopts a Fab structure to maintain binding affinity to PD-1 and thereby attain better enrichment in the tumor microenvironment". at a cost of a little more tox than other anti-PD-1 Fabs"
X Link @spontonic 2025-10-17T16:53Z XXX followers, XXX engagements

"$CHRS more on casdo relevant theme. "interleukin-27 receptor is essential for tumor growth control mediated by Stub1/Chic2 knockout CD8+ T cells""
X Link @spontonic 2025-08-13T15:26Z XXX followers, XXX engagements

"Would love to see Fleetwood win it all. "making #CCR8 and similar proteins more tractable for biochemical studies antibody development and therapeutic applications""
X Link @spontonic 2025-08-23T17:51Z XXX followers, XXX engagements

"@qniatof $BMY #CCR8 And relevant the "hell freezes over" trial completion date has been extended by X full years to 2028"
X Link @spontonic 2025-09-24T00:13Z XXX followers, XXX engagements

"@qniatof 2/ could get a little weird. M.D. Anderson launching a phase II as $BMY extends its phase I by another X years is just more of the same. But I'm leaning toward LaNova Shionogi AND BMY being "go". Would be great to have a comparative handle on epitope definition"
X Link @spontonic 2025-09-24T21:19Z XXX followers, XXX engagements

"#CCR8 Shimon Sakaguchi and the Nobel Prize in Physiology or Medicine 2025. among other accomplishments"
X Link @spontonic 2025-10-06T20:58Z XXX followers, XXX engagements

"Anti-#CCR8 MAb S-531011 Shionogi"
X Link @spontonic 2025-10-07T21:07Z XXX followers, XXX engagements

"Sort of figured. But of course AI agents do make mistakes and can't predict a future shaped by existing but unforeseen biology. Junshi attempting to use tori's own Fab to cut into its partner's sales"
X Link @spontonic 2025-10-17T18:21Z XXX followers, XX engagements

"Amgen v. Sanofi: The 2023 Supreme Court ruling in Amgen v. Sanofi affirmed the need for patents to sufficiently enable the full scope of a claimed invention reinforcing the idea that broad speculative claims are not valid. By analogy a license"
X Link @spontonic 2025-10-17T18:26Z XXX followers, XX engagements